BDBM230113 US10106559, Example 43::US10435415, Example 43::US9334290, 42::US9334290, 43::US9850258, Example 43

SMILES Cn1c2ccccc2c(=O)n(-c2cccc(c2Cl)-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(ccc4c23)C(C)(C)O)c1=O

InChI Key InChIKey=JDCRUGNUAHGYLE-UHFFFAOYSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 230113   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2.00E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  1.20E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2.00E+3nMpH: 7.4 T: 2°CAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substrates ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  1.20E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  0.470nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  1.20E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  0.470nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2.00E+3nMAssay Description:The assays were performed in V-bottom 384-well plates. The final assay volume was 30 μl prepared from 15 μl additions of enzyme and substra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  2nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  1.20E+3nMAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  0.470nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230113(US10106559, Example 43 | US10435415, Example 43 | ...)
Affinity DataIC50:  0.470nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent